Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 – December 2019
Lore Merdrignac,Fatima Aït El Belghiti,Elisabetta Pandolfi,Lesly Acosta,Kateřina Fabiánová,Adele Habington,Manuel García Cenoz,Håkon Bøås,Julie Toubiana,Alberto E. Tozzi,Iolanda Jordan,Jana Zavadilová,Niam O'Sullivan,Ana Navascués,Elmira Flem,Ilena Croci,Mireia Jané,Pavla Křížová,Suzanne Cotter,Leticia Fernandino,Terese Bekkevold,Carmen Muñoz-Almagro,Sabrina Bacci,Piotr Kramarz,Esther Kissling,Camelia Savulescu,Renacoq Group,the PERTINENT Group
DOI: https://doi.org/10.1016/j.vaccine.2024.02.090
IF: 4.169
2024-03-14
Vaccine
Abstract:Background Monitoring effectiveness of pertussis vaccines is necessary to adapt vaccination strategies. PERTINENT, Pertussis in Infants European Network, is an active sentinel surveillance system implemented in 35 hospitals across six EU/EEA countries. We aim to measure pertussis vaccines effectiveness (VE) by dose against hospitalisation in infants aged <1 year. Methods From December 2015 to December 2019, participating hospitals recruited all infants with pertussis-like symptoms. Cases were vaccine-eligible infants testing positive for Bordetella pertussis by PCR or culture; controls were those testing negative to all Bordetella spp. For each vaccine dose, we defined an infant as vaccinated if she/he received the corresponding dose >14 days before symptoms. Unvaccinated were those who did not receive any dose. We calculated (one-stage model) pooled VE as 100*(1-odds ratio of vaccination) adjusted for country, onset date (in 3-month categories) and age-group (when sample allowed it). Results Of 1,393 infants eligible for vaccination, we included 259 cases and 746 controls. Median age was 16 weeks for cases and 19 weeks for controls (p < 0.001). Median birth weight and gestational age were 3,235 g and week 39 for cases, 3,113 g and week 39 for controls. Among cases, 119 (46 %) were vaccinated: 74 with one dose, 37 two doses, 8 three doses. Among controls, 469 (63 %) were vaccinated: 233 with one dose, 206 two doses, 30 three doses. Adjusted VE after at least one dose was 59 % (95 %CI: 36–73). Adjusted VE was 48 % (95 %CI: 5–71) for dose one (416 eligible infants) and 76 % (95 %CI: 43–90) for dose two (258 eligible infants). Only 42 infants were eligible for the third dose. Conclusions Our results suggest moderate one-dose and two-dose VE in infants. Larger sample size would allow more precise estimates for dose one, two and three.
immunology,medicine, research & experimental